These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24612173)

  • 21. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment.
    Ungerleider NA; Rao SG; Shahbandi A; Yee D; Niu T; Frey WD; Jackson JG
    Breast Cancer Res; 2018 Oct; 20(1):115. PubMed ID: 30285883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma.
    Peiró G; Adrover E; Sánchez-Tejada L; Lerma E; Planelles M; Sánchez-Payá J; Aranda FI; Giner D; Gutiérrez-Aviñó FJ
    Mod Pathol; 2011 Feb; 24(2):201-8. PubMed ID: 21057462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers.
    Takahashi M; Tonoki H; Tada M; Kashiwazaki H; Furuuchi K; Hamada J; Fujioka Y; Sato Y; Takahashi H; Todo S; Sakuragi N; Moriuchi T
    Int J Cancer; 2000 Jan; 89(1):92-9. PubMed ID: 10719737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular and immunophenotypic characterization of anal squamous cell carcinoma reveals distinct clinicopathologic groups associated with HPV and TP53 mutation status.
    Zhu X; Jamshed S; Zou J; Azar A; Meng X; Bathini V; Dresser K; Strock C; Yalamarti B; Yang M; Tomaszewicz K; Tjionas G; Mochel MC; Hutchinson L; Bledsoe JR
    Mod Pathol; 2021 May; 34(5):1017-1030. PubMed ID: 33483624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Definition of p53 overexpression and its association with the clinicopathological features in luminal/HER2-negative breast cancer.
    Kikuchi S; Nishimura R; Osako T; Okumura Y; Nishiyama Y; Toyozumi Y; Arima N
    Anticancer Res; 2013 Sep; 33(9):3891-7. PubMed ID: 24023325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.
    Sicking I; Rommens K; Battista MJ; Böhm D; Gebhard S; Lebrecht A; Cotarelo C; Hoffmann G; Hengstler JG; Schmidt M
    BMC Cancer; 2014 Dec; 14():952. PubMed ID: 25511800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of TP53 alterations in breast carcinoma.
    Andersen TI; Holm R; Nesland JM; Heimdal KR; Ottestad L; Børresen AL
    Br J Cancer; 1993 Sep; 68(3):540-8. PubMed ID: 8102535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p53 protein expression patterns associated with TP53 mutations in breast carcinoma.
    Anderson SA; Bartow BB; Harada S; Siegal GP; Wei S; Dal Zotto VL; Huang X
    Breast Cancer Res Treat; 2024 Aug; 207(1):213-222. PubMed ID: 38900212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.
    Ozcelik H; Pinnaduwage D; Bull SB; Andrulis IL
    Breast Cancer Res Treat; 2007 Nov; 105(3):255-65. PubMed ID: 17221157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators.
    Patel DD; Bhatavdekar JM; Chikhlikar PR; Ghosh N; Suthar TP; Shah NG; Mehta RH; Balar DB
    J Surg Oncol; 1996 Jun; 62(2):86-92. PubMed ID: 8649046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
    Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
    Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
    Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
    Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.
    Li JP; Zhang XM; Zhang Z; Zheng LH; Jindal S; Liu YJ
    Medicine (Baltimore); 2019 May; 98(18):e15449. PubMed ID: 31045815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of immunohistochemically detected p53 accumulation in prognosis of breast cancer; A retrospective survey of outcome.
    Sadighi S; Zokaasadi M; Kasaeian A; Maghsudi S; Jahanzad I; Kamranzadeh Fumani H
    PLoS One; 2017; 12(8):e0182444. PubMed ID: 28771563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. c-erbB-2 protein level in tissue and sera of breast cancer patients: a possibly useful clinical correlation.
    Quaranta M; Daniele A; Coviello M; Savonarola A; Abbate I; Venneri MT; Paradiso A; Stea B; Zito A; Labriola A; Schittulli F
    Tumori; 2006; 92(4):311-7. PubMed ID: 17036522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.